Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease. Here, DDR1 is linked to early-onset autosomal dominant Alzheimer disease.